Abstract
‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Current Pharmaceutical Design
Title: Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Volume: 17 Issue: 12
Author(s): Paula J. Edge and Mark S. Gold
Affiliation:
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Abstract: ‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Export Options
About this article
Cite this article as:
J. Edge Paula and S. Gold Mark, Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656738
DOI https://dx.doi.org/10.2174/138161211795656738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptors and the Control of Fatty Acid Oxidation in Cardiac Hypertrophy
Mini-Reviews in Medicinal Chemistry CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology
Current Gene Therapy Harnessing Metabolomics for Nutrition Research
Current Pharmaceutical Biotechnology Olive Oil and Haemostasis
Current Nutrition & Food Science Recent Patents on the Use of Antioxidant Agents in Food
Recent Patents on Food, Nutrition & Agriculture Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Value of Coronary Calcium Scoring in Symptomatic and Asymptomatic Coronary Artery Disease Patients
Current Medical Imaging Beta-arrestin Biased Agonism/Antagonism at Cardiovascular Seven Transmembrane-spanning Receptors
Current Pharmaceutical Design The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Advances in the Pharmacokinetics of Natural Bioactive Polyphenols)
Current Drug Metabolism Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Clinical Application of PET Myocardial Perfusion Imaging
Current Medical Imaging Effects of Ox Bile Extract on the Phospholipids and Fatty Acids Membrane Composition of Salmonella enterica Serovar Typhimurium seqA Mutant Strain
Current Chemical Biology The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) Erythropoietin and Oxidative Stress
Current Neurovascular Research subject Index To Volume 3
Current Drug Targets Therapeutic Targeting of P-Selectin in Atherosclerosis
Inflammation & Allergy - Drug Targets (Discontinued) The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews